Your browser doesn't support javascript.
loading
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Juan-Giner, Aitana; Kimathi, Derick; Grantz, Kyra H; Hamaluba, Mainga; Kazooba, Patrick; Njuguna, Patricia; Fall, Gamou; Dia, Moussa; Bob, Ndeye S; Monath, Thomas P; Barrett, Alan D; Hombach, Joachim; Mulogo, Edgar M; Ampeire, Immaculate; Karanja, Henry K; Nyehangane, Dan; Mwanga-Amumpaire, Juliet; Cummings, Derek A T; Bejon, Philip; Warimwe, George M; Grais, Rebecca F.
Afiliação
  • Juan-Giner A; Epicentre, Paris, France.
  • Kimathi D; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK.
  • Grantz KH; Department of Biology, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Hamaluba M; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK.
  • Kazooba P; Epicentre Mbarara Research Centre, Mbarara, Uganda.
  • Njuguna P; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Fall G; Institut Pasteur Dakar, Dakar, Senegal.
  • Dia M; Institut Pasteur Dakar, Dakar, Senegal.
  • Bob NS; Institut Pasteur Dakar, Dakar, Senegal.
  • Monath TP; Crozet BioPharma LLC, Devens, MA, USA.
  • Barrett AD; Sealy Institute for Vaccines Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
  • Hombach J; Immunization, Vaccines & Biologicals, WHO, Geneva, Switzerland.
  • Mulogo EM; Department of Community Health, Mbarara University of Science & Technology, Mbarara, Uganda.
  • Ampeire I; Expanded Program on Immunization, Ministry of Health, Kampala, Uganda.
  • Karanja HK; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Nyehangane D; Epicentre Mbarara Research Centre, Mbarara, Uganda.
  • Mwanga-Amumpaire J; Epicentre Mbarara Research Centre, Mbarara, Uganda.
  • Cummings DAT; Department of Biology, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
  • Bejon P; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK.
  • Warimwe GM; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK.
  • Grais RF; Epicentre, Paris, France. Electronic address: rebecca.grais@epicentre.msf.org.
Lancet ; 397(10269): 119-127, 2021 01 09.
Article em En | MEDLINE | ID: mdl-33422245
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Febre Amarela / Uso Off-Label Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Febre Amarela / Uso Off-Label Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França